Metastatic prostate cancer in transsexual patient – PubMed
We report a case of a male-to-female transgender woman who was diagnosed with metastatic prostate cancer, 31 years post-feminization.
What is it lately with the journals and reports of cancer in trans patients? This is the third one in a month!
This one’s actually interesting, from a medical perspective, since it involves prostate cancer. Prostate cancer is supposed to be one of those things transwomen need to worry LESS about, since HRT more or less shrinks the prostate into nothingness.
The patient in this case had SRS in 1970 and since then had been on “conjugated estrogen tablets 1.25 mg daily with no other hormone manipulation therapy.” Note that SRS includes, of course, bilateral orchiotomy, which is a common step taken to cure prostate cancer. In other words, this patient had a non-functioning, shrunken prostate and no real T levels to worry about. Yet still she ended up with prostate cancer.
The article goes on to describe how she presented with the cancer in 2000. She underwent various treatments, including chemotherapy and the introduction of an anti-androgen, and had some improvement. In 2007, she died from “a thromboembolic event” — i.e. complications from blood clots, something transwomen are known to be at increased risk for, and also something that cancer patients are also known to be at increased risk for. In other words, for a transwoman with cancer, thrombosis is a definite issue.
Transwomen have unique bodies. We’re constantly fighting against our DNA. This case is a reminder that, even years after we’ve “won” the battle, we still need to be thinking about our unique medical needs and risks.